Related Experiment Video
Updated: Sep 2, 2026

The Creation of a Rat Model for Osteosarcopenia via Ovariectomy
Published on: February 21, 2025
Sarcopenia, obesity, sarcopenic obesity and dementia risk: a systematic review and meta-analysis of cohort studies
Uraiporn Booranasuksakul1, Zhongyang Guan2, Leticia Radin Pereira3
1Faculty of Allied Health Sciences, Burapha University, Saen Suk, Thailand.
Abstract:
Sarcopenia and obesity, characterised respectively by reduced muscle mass and function and increased adiposity, may co-occur as sarcopenic obesity (SO). This systematic review summarises cohort evidence linking these body composition phenotypes to dementia risk. MEDLINE, EMBASE, Cochrane Database and PsycINFO were searched from inception to February 2026. Outcomes included incident all-cause dementia (ACD) and subtypes. Pooled hazard ratios were calculated for each phenotype using random-effects models. Fourteen publications were included for sarcopenia, 72 for obesity, and four for SO. Late-life obesity (≥65 years) was protective for ACD (HR 0.83, 95% CI 0.76-0.89), whereas mid-life obesity (<65 years) modestly increased risk (HR 1.09, 95% CI 1.01-1.16). Sarcopenia was associated with increased risk (HR 1.42, 95% CI 1.26-1.58). SO showed no significant association (HR 1.43, 95% CI 0.87-1.99). These findings highlight age-dependent effects of obesity and an elevated dementia risk with sarcopenia; the predictive role of SO requires further research.
Related Concept Videos
Obesity
Pharmacodynamics in Geriatric Patients: Effects of Age
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
The Effect of Aging on Tissues
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution